Ketoconazole (ketoconazole)

No dosing information is available for this tab.

Ketoconazole is administered orally.

If used in patients receiving a drug that decreases gastric acid output or increases gastric pH, ketoconazole tablets should be administered with an acidic beverage (e.g., non-diet cola) and the acid-reducing drug should be administered at least 1 hour before or 2 hours after ketoconazole. (See Drug Interactions: Drugs Affecting Gastric Acidity.)

To ensure absorption in patients with achlorhydria(see Pharmacokinetics: Absorption), some clinicians have suggested that each 200-mg dose of oral ketoconazole should be administered with an acidic beverage (e.g., Coca-Cola(R), Pepsi(R)) or the dose dissolved in 60 mL of citrus juice; however, this strategy may not be adequate in all patients with achlorhydria and patients should be monitored closely for therapeutic failure.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

• No disease contraindications

There is no enhanced messaging for this drug.

Rare or Very Rare

• Anaphylaxis
• Angioedema

More Frequent

• Pruritus of skin
• Skin inflammation
• Skin irritation

Rare or Very Rare

• Abnormal hair texture
• Alopecia
• Cheilitis
• Dermatitis due to topical drug
• Dry skin
• Erythema
• Hair discoloration
• Skin rash
• Stinging of skin

No enhanced messaging available.

No enhanced messaging available.

Ketoconazole should be used during pregnancy only when potential benefits justify possible risks to the fetus.

Ketoconazole has been teratogenic (syndactylia and oligodactylia) when given orally to pregnant rats in a dosage of 80 mg/kg daily (2 times the maximum recommended human oral dosage based on body surface area comparisons). The drug has also been embryotoxic in rats when given orally during the first trimester of gestation in dosages exceeding 80 mg/kg daily and has caused dystocia in rats when given orally during the third trimester of pregnancy in dosages exceeding 10 mg/kg (approximately 25% of the maximum human dosage based on body surface area comparisons). Although these effects may be a reflection of the particular sensitivity of female rats to ketoconazole (maternal toxicity), there are no adequate and controlled studies to date using ketoconazole in pregnant women.

Because ketoconazole is distributed into human milk, lactating women receiving the drug should not breast-feed.

No enhanced messaging available.